Cargando…
Respiratory hospitalizations and respiratory syncytial virus prophylaxis in special populations
Palivizumab utilization, compliance, and outcomes were examined in infants with preexisting medical diseases within the Canadian Registry Database (CARESS) to aid in developing guidelines for potential “at-risk” infants in the future. Infants who received ≥1 dose of palivizumab during the 2006–2010...
Autores principales: | Paes, B., Mitchell, I., Li, A., Lanctôt, K.L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer-Verlag
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3327836/ https://www.ncbi.nlm.nih.gov/pubmed/22203430 http://dx.doi.org/10.1007/s00431-011-1654-8 |
Ejemplares similares
-
Erratum to: Respiratory hospitalizations and respiratory syncytial virus prophylaxis in special populations
por: Paes, B., et al.
Publicado: (2012) -
Respiratory Syncytial Virus Prophylaxis in Infants With Congenital Diaphragmatic Hernia in the Canadian Respiratory Syncytial Virus Evaluation Study of Palivizumab, 2005–2017
por: Kim, Doyoung, et al.
Publicado: (2019) -
A comparative study of respiratory syncytial virus (RSV) prophylaxis in premature infants within the Canadian Registry of Palivizumab (CARESS)
por: Paes, B., et al.
Publicado: (2012) -
First versus second year respiratory syncytial virus prophylaxis in chronic lung disease (2005–2015)
por: Wang, Daniel Y., et al.
Publicado: (2017) -
Respiratory Syncytial Virus Immunoprophylaxis with Palivizumab: 12-Year Observational Study of Usage and Outcomes in Canada
por: Mitchell, Ian, et al.
Publicado: (2021)